Oak PIPEs Clariant

Oak Investment Partners has agreed to buy up to $50 million worth of convertible preferred stock in Clarient Inc. (Nasdaq: CLRT), a provider of anatomic pathology and molecular testing services. The first $40 million is split up into two tranches, with Clarient receiving $29.1 million today. The final $10 million is dependent on mutual agreement of Oak and Clariant, which is using the PIPE to pay off debt.

DealsNorth AmericaUSBriefs